Mesoblast Limited (NASDAQ:MESO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday. The brokerage presently has a $6.50 price target on the stock. Zacks Investment Research‘s price target indicates a potential upside of 7.99% from the stock’s previous close.

According to Zacks, “Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. “

A number of other brokerages have also commented on MESO. BidaskClub lowered Mesoblast Limited from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th. Maxim Group set a $14.00 target price on Mesoblast Limited and gave the stock a “buy” rating in a research report on Wednesday, August 16th. Oppenheimer Holdings, Inc. began coverage on Mesoblast Limited in a research report on Thursday, August 31st. They set an “outperform” rating and a $16.00 target price for the company. Cantor Fitzgerald restated a “buy” rating and set a $20.00 target price on shares of Mesoblast Limited in a research report on Wednesday, August 30th. Finally, ValuEngine lowered Mesoblast Limited from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $13.14.

Shares of Mesoblast Limited (NASDAQ MESO) traded up 4.3172% during midday trading on Wednesday, reaching $6.0191. 47,290 shares of the company’s stock were exchanged. Mesoblast Limited has a 1-year low of $4.01 and a 1-year high of $12.50. The firm has a 50-day moving average of $6.04 and a 200-day moving average of $8.06. The company’s market capitalization is $511.29 million.

TRADEMARK VIOLATION WARNING: “Mesoblast Limited (MESO) Upgraded to “Buy” by Zacks Investment Research” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/04/mesoblast-limited-meso-upgraded-to-buy-by-zacks-investment-research.html.

Mesoblast Limited Company Profile

Get a free copy of the Zacks research report on Mesoblast Limited (MESO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Mesoblast Limited (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related companies with MarketBeat.com's FREE daily email newsletter.